Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer by Karlsson, Elin et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Gene expression variation to predict 10-year survival in 
lymph-node-negative breast cancer
Elin Karlsson*1, Ulla Delle1, Anna Danielsson1, Björn Olsson2, Frida Abel3, 
Per Karlsson4 and Khalil Helou1
Address: 1Department of Oncology, Institute of Clinical Sciences, Blå stråket 2, University of Gothenburg, SE-413 45, Göteborg, Sweden, 2School 
of Life Sciences, University College of Skövde, Box 408, SE-541 28, Skövde, Sweden, 3Genomics Core Facility, Medicinaregatan 5A, Box 413, SE-
405 30, Göteborg Sweden and 4Oncology section, Department of Oncology, Sahlgrenska University Hospital, Blå, stråket 2, University of 
Gothenburg, SE-413 45, Göteborg, Sweden
Email: Elin Karlsson* - elin.karlsson@oncology.gu.se; Ulla Delle - ulla.delle@oncology.gu.se; 
Anna Danielsson - anna.danielsson@oncology.gu.se; Björn Olsson - bjorn.olsson@his.se; Frida Abel - frida.abel@genomics.gu.se; 
Per Karlsson - per.karlsson@oncology.gu.se; Khalil Helou - khalil.helou@oncology.gu.se
* Corresponding author    
Abstract
Background: It is of great significance to find better markers to correctly distinguish between high-risk
and low-risk breast cancer patients since the majority of breast cancer cases are at present being
overtreated.
Methods: 46 tumours from node-negative breast cancer patients were studied with gene expression
microarrays. A t-test was carried out in order to find a set of genes where the expression might predict
clinical outcome. Two classifiers were used for evaluation of the gene lists, a correlation-based classifier
and a Voting Features Interval (VFI) classifier. We then evaluated the predictive accuracy of this expression
signature on tumour sets from two similar studies on lymph-node negative patients. They had both
developed gene expression signatures superior to current methods in classifying node-negative breast
tumours. These two signatures were also tested on our material.
Results: A list of 51 genes whose expression profiles could predict clinical outcome with high accuracy
in our material (96% or 89% accuracy in cross-validation, depending on type of classifier) was developed.
When tested on two independent data sets, the expression signature based on the 51 identified genes had
good predictive qualities in one of the data sets (74% accuracy), whereas their predictive value on the
other data set were poor, presumably due to the fact that only 23 of the 51 genes were found in that
material. We also found that previously developed expression signatures could predict clinical outcome
well to moderately well in our material (72% and 61%, respectively).
Conclusion: The list of 51 genes derived in this study might have potential for clinical utility as a
prognostic gene set, and may include candidate genes of potential relevance for clinical outcome in breast
cancer. According to the predictions by this expression signature, 30 of the 46 patients may have benefited
from different adjuvant treatment than they recieved.
Trial registration: The research on these tumours was approved by the Medical Faculty Research Ethics
Committee (Medicinska fakultetens forskningsetikkommitté, Göteborg, Sweden (S164-02)).
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Background
Since the prevalence of breast cancer among women is
very high (one out of eight American women is affected in
their life-time [1]) the economical burden for the treat-
ment is considerable, as well as the suffering it causes.
After surgery the majority of breast cancer cases are at the
present over-treated since adequate diagnostic markers are
not currently available. Therefore it is important to find
better markers to correctly distinguish between the high-
risk patients that need additional treatment and the low-
risk patients where further treatment after surgery will
have no positive effect and might actually harm the
patient. At present, the most relevant marker in breast can-
cer diagnostics is the lymph-node status of the patient.
Although lymph-node negative breast cancer patients
have a better survival rate than patients with metastasis
positive lymph nodes, around 20% will succumb to their
cancer in less than 15 years [2]. In this study, gene expres-
sion microarrays were used to find a set of genes whose
expression profiles can predict clinical outcome in lymph-
node negative breast cancer patients. We also wanted to
evaluate our results on data sets derived from similar stud-
ies done previously on tumours from lymph-node nega-
tive patients [3,4].
Methods
Tumour material
Breast tumours from 46 patients consisting of two groups
were used, 23 tumours from 10-year survivors and 23
tumours from patients that died within 10 years from
diagnosis. The tumours were collected between 1990 and
1998 in the region Västra Götaland in Sweden. Clinical
information about the tumours used in the study is com-
piled in table 1 and in more detail in additional data file
1; Clinical data of each patient. The median follow-up
time among the survivors was 11.5 years (mean 11.8
years, range 10.4 to 15.3 years). In order to achieve a ten
year follow-up and mitigate age-related diseases, samples
were preferably selected from patients with a mean age
and tumour size of 50 years old and 27 mm, respectively.
Thus, age and size are not random and a multivariate
analysis is therefore not possible. In addition, patients
that died in intercurrent disease were excluded from the
study. The research on these tumours was approved by the
Medical Faculty Research Ethics Committee (Medicinska
fakultetens forskningsetikkommitté, Göteborg, Sweden
(S164-02)).
Representative imprints from each of the frozen tumours
were evaluated for the ratio of cancer/normal cells. The
imprints were air dried and stained with May-Grünwald-
Giemsa (Chemicon, Temecula, CA, USA). The presence of
at least 50% cancer cells was required for the specimen to
be included in this study.
Expression profiling
Microarrays were produced at the Swegene DNA Microar-
ray Resource Center, Department of Oncology, Lund Uni-
versity, Sweden [5]. Human array-ready 70-mer
oligonucleotide libraries Version 3.0, comprising approx-
imately 35 000 unique probes, were obtained from
Operon (Operon Biotechnologies, Germany). Probes
were dissolved in Corning Universal Spotting solution
(Corning, Acton, MA, USA) at a concentration of 24 μM
and printed on aminosilane coated glass slides (Ultra-
GAPS, Corning) using a MicroGrid2 robot (BioRobotics,
Cambridgeshire, UK) equipped with MicroSpot 10 K pins
(BioRobotics). Following printing, the arrays were left in
a desiccator to dry for 48 hours, and then UV cross-linked
(800 mJ/cm2).
Frozen tumours were homogenized in TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA) using a Micro-Dismem-
brator S (B. Braun Biotech International, Melsungen, Ger-
Table 1: Compilation of clinical data of the breast cancer 
patients used in the study.
10-year survivors deceased Total
Mean age 48 53 50
Surgery
breast preserving 11 11 22
mastectomy 12 12 24
total 23 23 46
Histology
ductal 19 14 33
lobular 1 2 3
mucinous 2 0 2
medullary 0 1 1
tubular 0 1 1
comedocarcinoma 0 1 1
adenocarcinoma 0 1 1
not available 1 3 4
total 23 23 46
Receptor Status
estrogen positive 12 11 23
progesterone positive 11 5 16
unavailable 1 0 1
Ploidi
diploid 7 3 10
aneuploid 13 13 26
polyploid 2 2 4
not available 1 5 6
total 23 23 46
S-phase
< 12% 14 7 21
>= 12% 3 8 11
not available 6 8 14
total 23 23 46BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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many). From the cell-suspension total RNA was extracted
using RNeasy mini kit (Qiagen, Valencia, CA, USA)
according to the manufacturer's protocol. The quality of
the RNA was evaluated with the Agilent 2100 BioAnalyser
(Agilent Technologies, Palo Alto, CA, USA). Specimens
where the 28S/18S ratio was lower than 1.0 or the RNA
integrity number (RIN) -value [6] was lower than 6.7 were
excluded from the study. For each sample, probes labelled
with Cy3-dCTP (Amersham Biosciences, Buckingham-
shire, UK) were synthesized from 5 μg of the total tumour
RNA and reference labelled with Cy5-dCTP (Amersham
Biosciences) was synthesized from 5 μg of commercial ref-
erence RNA (Universal Human Reference RNA, Strata-
gene, La Jolla, CA, USA) by reverse transcription. The
probes were purified using ChipShot™ labelling cleanup
system (Promega, Madison, WI, USA). The hybridizations
were carried out using Pronto! Micro Array reagent sys-
tems (Corning Inc., Corning, NY, USA). For each sample,
labelled tumour cDNA and reference cDNA were co-pre-
cipitated and hybridised to the microarray slide. The
microarray slides were scanned with Agilent microarray
scanner G2565AA (Agilent Technologies) and image anal-
ysis was performed using the Genepix 6.0.0.45 software
(Axon Instruments, Union City, CA, USA). The expression
data is available online at the Gene Expression Omnibus
repository [7,8], accession number GSE12071.
Data analysis
The first steps of data analysis were performed in BioArray
Software Environment (BASE) [9,10]. The intensities of
the spots were calculated by subtracting median back-
ground intensity from median spot intensity. Flagged
spots and spots for which background adjusted intensities
were < 0 or > 65 000 were excluded from further analysis.
Spots with intensities below 20 in both channels were
also excluded and intensities below 20 in one channel
were set to 20 to compensate for extreme quotients. These
steps reduced the number of genes from 34 659 to 31 564.
Fluorescence ratios were calculated as intensity tumour/
intensity reference. Each array was separately normalised
using pin-based Lowess normalization with 12 blocks in
each group. Reporters that were missing in more than
20% of the arrays were removed from the analysis. This
reduced the dataset from 31 564 to 16 023 genes remain-
ing for the statistical analysis. To identify differently
expressed genes a t-test was applied and a list of 55 report-
ers with p < 0.001 was derived. All 55 genes also had p <
0.01 in a Mann-Whitney test and 37 of the genes showed
Mann-Whitney p-values < 0.001. In order to avoid elimi-
nation of true positive genes, a low p-value threshold was
used instead of false discovery rate (FDR) adjustment.
Consequently, it is expected that 16 of the 55 genes might
be false positives (29%), but the evaluation indicates that
there is nevertheless a significant value of the expression
signature as predictor of clinical outcome in breast cancer.
Four of the 55 genes were not found in Entrez gene [11]
and could not be connected to any known gene by a
BLAST search with 100% correspondence. They were
therefore excluded.
The 51 remaining significant genes (table 2) were used for
hierarchical clustering of the samples using Euclidian dis-
tance and average linkage (UPGMA) in the PermutMatrix
software [12]. We also tested a correlation-based classifier
similar to the one van't Veer et al. used [3]. For the corre-
lation classifier the log-ratio values were normalised to the
scale [0–1] for each gene. Accuracy was calculated as the
number of correctly classified samples divided by the total
number of samples and the Negative Predictive Value
(NPV) was calculated as the number of samples correctly
classified as "good prognosis" divided by the total
number of samples classified as "good prognosis". The
threshold for the "good prognosis group" was set to 0.3
since it showed the highest NPV and a high accuracy. Kap-
lan-Meier curves were calculated for the "good prognosis
group" and the "bad prognosis group".
In addition, forty-three classification methods available in
the Weka software [13] were tested for their ability to clas-
sify the tumours. Each method was evaluated using leave-
one-out cross-validation (46 testing and training cycles
per method, using 45 samples for training and the
remaining sample for testing in each run, and with each
test-classification being considered correct if the left-out
sample is classified in the correct survival group). The VFI
classifier [14] turned out to achieve best results (addi-
tional data file 2. Classification results for our own data).
Data sets from other investigations with node-negative
breast cancer tumours [3,4] were used for evaluation of
our list of genes in order to validate our findings. We used
the VFI classifier (since it performed best on our material)
and the correlation-based classifier (since it was used by
van't Veer et al. [3]) to evaluate the predictive performance
of our genes in the other sets of tumours. Furthermore,
these two studies generated two different gene sets con-
taining 70 and 76 genes, respectively, with the ability to
predict metastasis within five years [3,4]. We tested the
prediction value of the expression signatures from these
gene lists on our tumours by the VFI classification method
and correlation-based classification (using the same
threshold for our data as earlier, i.e. 0.3).
Another analysis was performed in BASE using only
reporters present in the entire assay-set A t-test analysis
was carried out and resulted in 94 reporters that differed
significantly between the tumours from 10-year survivors
and the tumours from deceased patients with p-values
lower than 0.01.BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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Table 2: The genes that significantly differed between survivors and deceased patients.
A
Gene Symbol Accesion number Gene Name Expression 
deceased vs 10-year 
survivors
Gene Ontology, Function van't Veer/Wang
ADA NM_000022 adenosine deaminase Higher adenosine deaminase activity, 
hydrolase activity
1/1
BCAT1 NM_005504 branched chain 
aminotransferase 1, 
cytosolic
Higher branched-chain-amino-acid 
transaminase activity, 
catalytic activity, transferase 
activity
1/1
C9orf164 NM_006378 chromosome 9 open 
reading frame 164
Higher 0/0
CCDC99 NM_017785 coiled-coil domain 
containing 99
Higher 1/0
CCNB1IP1 NM_182849 cyclin B1 interacting 
protein 1
Higher ligase activity, metal ion 
binding
1/1
COMMD9 NM_014186 COMM domain containing 
9
Higher 0/1
CPS1 NM_001875 carbamoyl-phosphate 
synthetase 1, 
mitochondrial
Higher ATP binding, carbamoyl-
phosphate synthase 
(ammonia) activity, ligase 
activity, nucleotide binding, 
protein binding
1/2
E2F2 NM_004091 E2F transcription factor 2 Higher protein binding, transcription 
factor activity
1/1
F2 NM_000506 coagulation factor II 
(thrombin)
Higher calcium ion binding, receptor 
binding, thrombin activity, 
thrombin activity
1/1
GGH NM_003878 gamma-glutamyl hydrolase 
(conjugase, 
folylpolygammaglutamyl 
hydrolase)
Higher exopeptidase activity, 
hydrolase activity
1/1
GIT2 NM_014776 G protein-coupled 
receptor kinase interactor 
2
Higher GTPase activator activity, 
metal ion binding
2/2
GNG10 NM_004125 guanine nucleotide binding 
protein (G protein), 
gamma 10
Higher GTPase activity, heat shock 
protein binding, signal 
transducer activity
1/0
HPS5 NM_007216 Hermansky-Pudlak 
syndrome 5
Higher protein binding 1/1
KCNAB2 NM_003636 potassium voltage-gated 
channel, shaker-related 
subfamily, beta member 2
Higher ion channel activity, 
oxidoreductase activity, 
potassium channel regulator 
activity, potassium ion 
binding
1/0
MGC13057 NM_032321 hypothetical protein 
MGC13057
Higher 0/0
MRTO4 NM_016183 mRNA turnover 4 
homolog (S. cerevisiae)
Higher 0/1BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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MTERF NM_006980 mitochondrial 
transcription termination 
factor
Higher DNA binding, double-
stranded DNA binding, 
transcription termination 
factor activity
1/1
MYO1G NM_033054 myosin IG Higher ATP binding, motor activity 0/0
NPM3 NM_006993 nucleophosmin/
nucleoplasmin, 3
Higher nucleic acid binding 1/0
PIR NM_003662 pirin 
(iron-binding nuclear 
protein)
Higher metal ion binding, 
transcription cofactor 
activity
1/1
PLEKHM2 XM_290944 pleckstrin homology 
domain containing, family 
M (with RUN domain) 
member 2
Higher oxidoreductase activity 0/0
PRPS1L1 NM_175886 phosphoribosyl 
pyrophosphate synthetase 
1-like 1
Higher kinase activity, lipoate-
protein ligase B activity, 
magnesium ion binding, 
ribose phosphate 
diphosphokinase activity, 
transferase activity
0/1
RAB23 NM_183227 RAB23, member RAS 
oncogene family
Higher GTP binding, nucleotide 
binding
1/1
RCN1 NM_002901 reticulocalbin 1, EF-hand 
calcium binding domain
Higher calcium ion binding 0/0
RP5-1077B9.4 NM_021933 invasion inhibitory protein 
45
Higher 1/0
SALL4 NM_020436 sal-like 4 (Drosophila) Higher DNA binding, metal ion 
binding, nucleic acid binding, 
protein binding
0/0
SERPINB9 NM_004155 serpin peptidase inhibitor, 
clade B (ovalbumin), 
member 9
Higher protein binding, serine-type 
endopeptidase inhibitor 
activity
1/2
SLC35B4 NM_032826 solute carrier family 35, 
member B4
Higher UDP-N-acetylglucosamine 
transporter activity, UDP-
xylose transporter activity, 
nucleotide-sugar transporter 
activity, sugar porter activity
0/0
SPATA5 NM_145207 spermatogenesis 
associated 5
Higher ATP binding, nucleoside-
triphosphatase activity, 
nucleotide binding
0/0
TM4SF5 NM_003963 transmembrane 4 L six 
family member 5
Higher 1/0
TRPV2 NM_016113 transient receptor 
potential cation channel, 
subfamily V, member 2
Higher calcium ion binding, ion 
channel activity
2/0
B
Gene Symbol Accesion number Gene Name Expression 
deceased vs 10-year 
survivors
Gene Ontology, Function van't Veer/Wang
ARFIP1 NM_001025595 ADP-ribosylation factor 
interacting protein 1 
(arfaptin 1)
Lower identical protein binding 1/0
Table 2: The genes that significantly differed between survivors and deceased patients. (Continued)BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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ARSD NM_001669 arylsulfatase D Lower arylsulfatase activity, calcium 
ion binding, hydrolase activity
2/2
C1orf43 NM_015449 chromosome 1 open 
reading frame 43
Lower 1/0
C4orf26 NM_178497 chromosome 4 open 
reading frame 26
Lower 0/0
CCDC24 NM_152499 coiled-coil domain 
containing 24
Lower 0/0
CUL7 NM_014780 cullin 7 Lower protein binding 1/2
EDEM3 NM_025191 ER degradation enhancer, 
mannosidase alpha-like 3
Lower calcium ion binding, 
mannosyl-oligosaccharide 
1,2-alpha-mannosidase 
activity, peptidase activity
0/0
FAAH NM_001441 fatty acid amide hydrolase Lower amidase activity, hydrolase 
activity, receptor binding
2/1
FXYD3 NM_005971 FXYD domain containing 
ion transport regulator 3
Lower chloride ion binding, ion 
channel activity
1/0
GOLT1A NM_198447 golgi transport 1 homolog 
A (S. cerevisiae)
Lower 1/0
NEIL1 NM_024608 nei endonuclease VIII-like 
1 (E. coli)
Lower DNA N-glycosylase activity, 
damaged DNA binding, 
hydrolase activity, acting on 
glycosyl bonds, lyase activity, 
oxidized purine base lesion 
DNA N-glycosylase activity, 
zinc ion binding
1/0
OR7E91P NR_002185 olfactory receptor, family 
7, subfamily E, member 91 
pseudogene
Lower receptor activity 0/0
PHLDA3 NM_012396 pleckstrin homology-like 
domain, family A, member 
3
Lower 1/0
PLEKHA6 NM_014935 pleckstrin homology 
domain containing, family 
A member 6
Lower 1/1
RORC NM_005060 RAR-related orphan 
receptor C
Lower metal ion binding, sequence-
specific DNA binding, steroid 
hormone receptor activity, 
transcription factor activity
1/1
TAF5L NM_014409 TAF5-like RNA 
polymerase II, p300/CBP-
associated factor (PCAF)-
associated factor, 65 kDa
Lower transcription factor activity 1/1
TMEM63A NM_014698 transmembrane protein 
63A
Lower 1/4
ZNF497 NM_198458 zinc finger protein 497 Lower metal ion binding, nucleic 
acid binding
0/0
ZNF691 NM_015911 zinc finger protein 691 Lower metal ion binding, nucleic 
acid binding
0/0
ZNF692 NM_017865 zinc finger protein 692 Lower metal ion binding, nucleic 
acid binding
1/0
A, Biological function of the genes with significantly higher expression in the tumours from deceased patients compared to the tumours from 10-
year survivors.
B, Biological function of the genes with significantly lower expression in the tumours from deceased patients compared to the tumours from 10-
year survivors.
Gene Symbol, Gene Name and Gene Ontology information was captured from Entrez Gene. The last column shows the number of replicates in the 
suydies by van't Veer et al. and Wang et al., respectively.
Table 2: The genes that significantly differed between survivors and deceased patients. (Continued)BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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Real-time RT-PCR with TaqMan
Fourteen genes that had high overall expression were
selected from the 51 gene list and the 94 gene list of sig-
nificantly differentially expressed genes, and scrutinized
using Real-time RT-PCR with Taqman (table 3). Another
two genes with homogenous expression throughout the
expression array analysis were used for normalisation
(table 3). All tumours except four were used, due to the
lack of access to material. For each tumour, cDNA was
synthesized from 1 μg total RNA (from the same RNA
extraction as in the microarray experiment) using Super-
Script™ III First-Strand Synthesis SuperMix for qRT-PCR
(Invitrogen) according to the manufacturer's protocol.
Real-time RT-PCR was performed in 384-well plates using
the ABI PRISM®  7900HT Sequence Detection System
(Applied Biosystems, Foster City, USA). Commercially
available validated TaqMan®  Gene Expression Assays
(including cDNA-specific primers and probes) were
obtained from Applied Biosystems [15]. A keyword search
for each gene name or accession number was performed,
and the corresponding inventoried assay kit (500 reac-
tions) was ordered from the website.
The PCR set up was performed using the pipetting robot
Biomek FX (Beckman Coulter, Bromma, Sweden). Ampli-
fication reactions (10 μl) were carried out in triplicates
with 2 μl of 1:7 diluted cDNA template, 1 × TaqMan Uni-
versal PCR Master Mix (Applied Biosystems), 1 × FAM-
labelled TaqMan® Gene Expression Assays Mix (Applied
Biosystems) in the 384 well format. Thermal cycling was
performed using the 7900HT Sequence Detection System
(Applied Biosystems) with an initiation step at 95°C for
10 minutes, followed by 40 cycles of 15 seconds at 95°C
and 1 minute at 60°C. In each assay, a 2-fold dilution
series of five samples was recorded, and one no-template
control was included.
Quantification was performed by the standard-curve
method. In summary, a standard curve was recorded in
each PCR assay for all genes using serial dilutions (1:2,
1:4, 1:8, 1:16, 1:32) of calibrator cDNA (sample 7011).
The mean CT-value for triplicates was calculated, and the
relative gene concentration of test samples was interpo-
lated, based on the standard curve from the gene in ques-
tion. All samples were normalised to the geometric mean
of two endogenous controls; i.e. PPIA  and  PTER. The
results were evaluated by testing the difference between
the two groups using a one-sided Student's t-test.
Results
A list of 51 genes was used to cluster the tumours
Forty-six tumours were analysed by expression microarray
in order to identify genes whose expression could predict
clinical outcome in node-negative breast cancer. The gene
expression in 23 tumours from 10-year survivors was
compared to the gene expression in 23 tumours from
patients that died within ten years from diagnosis. The
data generated from the microarray study was analysed
using t-test analysis, resulting in a set of 51 genes that dif-
fered in average expression between the two groups of
tumours with p < 0.001 (table 2). This gene set was used
for hierarchical agglomerative clustering of the tumours
using Euclidian distance and average linkage (UPGMA),
resulting in two distinct clusters of tumours; one consist-
ing of only tumours from 10-year survivors (19 tumours)
and the second consisting of all 23 tumours from
deceased patients and four tumours from 10-year survi-
vors. Furthermore, the genes separated into four main
clusters, and these clusters were characterized by patterns
of up- or down-regulation (figure 1).
Classification of the tumours using the gene list
In order to evaluate if the list of 51 significant genes could
classify node-negative breast tumours into 10-year survi-
vors and deceased patients, a correlation-based classifier
Table 3: The genes used in Real-time RT-PCR.
Genes from the 51 gene list
Gene Symbol Acc. number validated
CCNB1IP1 NM_182849 yes
E2F2 NM_004091 yes
GGH NM_003878 yes
GIT2 NM_014776 yes
SERPINB9 NM_004155 yes
TMEM63A NM_014698 yes
ZNF497 NM_198458 no
ZNF691 NM_015911 no
Genes from the 94 gene list
Gene Symbol Acc. number validated
AKR1B1 NM_001628 yes
EGLN1 NM_022051 yes
HAX1 NM_006118 no
LGMN NM_005606 yes
SHC1 NM_003029 no
TFAP2A NM_003220 yes
Reference genes
Gene Symbol Acc. number
PPIA NM_203431
PTER NM_001001484
Eight genes from the list of 51 genes (p < 0.001 and 80% presence) 
were selected together with six genes from the list with 94 genes (p < 
0.01 and 100% presence), where p-values were below the significance 
level for the difference in average expression between 10 year 
survivors and deceased patients. Two genes were selected as 
reference genes since they had homogenous expression throughout 
the expression array analysis. The table also shows in which genes 
differences in expression between the two survival groups were 
validated using RT-PCR.BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
Page 8 of 14
(page number not for citation purposes)
using the same method as van't Veer et al. [3] were tested.
It resulted in an accuracy of 89% and 100% NPV in our
material (figure 2a).
Furthermore, the 43 classification methods available in
the Weka software was tested (additional data file 2. Clas-
sification results for our own data). All classification
methods were tested using leave-one-out cross-validation,
which repeatedly splits the samples into a test- and train-
ing set. The best-performing classifier, VFI, only misclassi-
fied two samples in the cross-validation. In general, non-
symbolic methods which use values from all genes for the
Hierarchical clustering of the 46 tumours and 51 genes using Euclidian distance and average linkage (UPGMA) Figure 1
Hierarchical clustering of the 46 tumours and 51 genes using Euclidian distance and average linkage (UPGMA). 
Green represents negative values compared to the reference, red represents positive values, black represents 0, and grey rep-
resents missing values. Arrows indicate samples from patients that survived more than 10 years after diagnosis. Patients sepa-
rated into two distinct clusters, one containing all deceased, together with only four survivors. The other cluster contained 
only tumours from survivors. Genes separated into four main clusters, characterized by distinct patterns of up- or down-regu-
lation.BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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classification performed better (average accuracy 85.4%, ±
4.8, 95% confidence interval) than symbolic methods
which attempt to single out a subset of genes on which to
base the classification (64.5%, ± 8.9). This result indicates
that all (or most) of the 51 genes contribute to the sur-
vival/non-survival outcome and that a prediction of the
outcome can not be based only on a small subset of these
genes.
Classification of other tumour sets using the 51 gene list
When we searched for our 51 genes in van't Veer's dataset
[3], 34 of them were found and used for classification
(four of them were found twice since they were repre-
sented by two replicates) (table 2). Their patients were
divided into three groups; patients that were free of dis-
ease for five years or more (44 patients), patients that
developed metastases within five years (32 patients), and
patients with BRCA mutations (18 patients). The patients
with BRCA mutations were not included in our classifica-
tion. The correlation-based classifier showed 74% accu-
racy (figure 2b). Furthermore, the training and testing
procedure, using leave-one-out cross validation, was
repeated using the 34 genes resulting in an accuracy of
67% with the VFI classifier. Four of our genes differed in
average expression with p < 0.05 between the metastasis
patients and the metastasis free patients (GGH,  PIR,
TAF5L and FAAH).
In Wang's data 23 of our 51 genes were found (six of them
were found as more than one replicate) (table 2). No spe-
cific pattern was seen and the patients that developed
metastasis within five years did not separate from the
metastasis free patients. In this data set three genes dif-
fered in average expression with p  < 0.05 between the
metastasis patients and the metastasis free patients
(RORC, FAAH and MRTO4).
Classification of our tumours using other gene-lists
Among the 70 significant genes identified in the study by
van't Veer, 46 genes were identified in our data (addi-
tional data file 3; Van't Veer's genes in our material), of
which 17 were found as more than one replicate. A VFI
classification of our data using these genes showed 67%
accuracy and correlation-based classification showed 72%
accuracy. Six deceased patients were classified in the
"good prognosis group" (figure 3a). Among Wang's 76
genes, 49 were found in our data set and 17 were found
more than once (additional data file 4; Wang's genes in
our material.). The VFI classifier showed 70% accuracy
with these genes and the correlation-based classifier
showed 61% accuracy and 59% NPV (figure 3b).
Results of the real-time RT-PCR
Differences in gene expression between the groups were
verified using Real-time RT-PCR in ten out of fourteen
Correlation-based classification using the 51 gene list Figure 2
Correlation-based classification using the 51 gene list. A, Classification of our tumours using our 51 genes. This shows 
89% accuracy and 100% NPV. B, Classification of van't Veer's tumours using our 51 genes shows 74% accuracy and 85% NPV. 
In A black bars represent 10-year survivors while white bars represent patients that died within ten years from diagnosis. In B, 
black bars represent patients that were metastasis free for five years, while white bars represent patients that developed 
metastasis within five years. Plots to the right show the correlation between each tumour's expression profile and the good 
prognosis profile.BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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genes (table 3). The failure in verifying all genes might be
due to sub optimal RNA quality.
Discussion
Expression microarray analysis was performed on 46
lymph-node negative breast cancer tumours divided into
two equally sized groups, where 23 tumours were from
10-year survivors and 23 tumours were from patients that
died within 10 years after diagnosis. Previously, 43 of
these tumours were included in a CGH study (Compara-
tive Genomic Hybridisation) that searched for chromo-
somal alterations differing between deceased patients and
10-year survivors [16]. The aim of this study was to search
for specific genes differentially expressed between the two
groups and test the prognostic potential of these genes on
other tumour sets. Previous studies have used expression
microarrays to find sets of genes whose expression could
predict clinical outcome in breast cancer or candidate
genes that could be correlated to prognostic features
[3,4,17-32]. Some of these studies focused on node-nega-
tive tumours [3,4,32]. We wanted to further expand the
current knowledge of the genetic events associated with
clinical outcome in lymph-node negative breast cancer
using tumours from a relatively homogenous population,
and compare our results with previous findings, particu-
larly focusing on the studies reported by van't Veer et al.
and Wang et al. [3,4], since both these studies developed
gene-lists superior to current methods in classifying node-
negative breast tumours.
A reporter list consisting of 51 genes with significant dif-
ferential expression between the two groups (p < 0.001)
was assembled. Hierarchical clustering using these genes
resulted in two clusters, separating the two survival groups
with only four survivor tumours misclassified (figure 1).
Only two tumours were incorrectly classified in the cross-
validation using the VFI classification algorithm (accuracy
rate: 96%). The correlation-based classifier showed 89%
accuracy and 100% NPV (figure 2a). We considered the
NPV to be particularly important as it reflects the patient's
probability to survive ten years after diagnosis if it is clas-
sified into the "good prognosis group". No patient in the
"good prognosis group" died within ten years from diag-
nosis, which is visualized in the Kaplan-Meier curves (fig-
ure 4). Among the 18 patients that were classified in the
"good prognosis group", which would not benefit from
further treatment, 13 had been post-surgically treated by
radio therapy, chemo therapy, hormonal treatment or a
combinatory treatment (additional data file 1. Clinical
data of each patient.). On the other hand, in the "bad
prognosis group" 16 of the patients did not receive post-
surgical treatment which they should have according to
this study (of these, three were incorrectly classified 10
year survivors). Consequently, based on the results gener-
ated from the classifier using the 51 genes, the adjuvant
treatment among many patients in this particular material
would be reconsidered. Furthermore, the tumours within
each group show similar patterns of gene expression in the
51 selected genes and these specific genes are relevant for
predicting clinical outcome in our tumour material.
In order to test this gene-list further, we analysed its pre-
dictive potential in two independent data sets [3,4]. Van't
Veer et al. identified a set of 70 genes to classify 78 node-
Correlation-based classification of our tumours using other gene lists Figure 3
Correlation-based classification of our tumours using other gene lists. A, Classification of our tumours using van't 
Veer's genes, 72% accuracy and 73% NPV. B, Classification of our tumours using Wang's genes, 61% accuracy and 59% NPV. 
Black bars represent 10-year survivors while white bars represent patients that died within ten years from diagnosis.BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
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negative breast tumours from young women into poor
and good prognostic groups with an accuracy of 83%
(81% when the classification threshold were calibrated so
that less than 10% of the metastasis patients were classi-
fied in the "good prognosis group") [3]. Another study by
van de Vijver et al. confirmed the relevance of the 70-gene
classifier on 295 tumours, of which 151 were from node-
negative patients [33]. This classifier was designed to not
classify tumours from deceased patients into the "good
prognosis" group, and few of the incorrectly classified
tumours are from patients where the disease recurred in
both studies. Recently, a mini-microarray customised
based on this 70-gene classifier was tested on 162 of the
lymph node-negative patients used in the previous two
studies with good prognostic correlation [34]. In another
study of node-negative breast cancer by Wang et al., a 76-
gene signature that correlated to disease-free 5-year sur-
vival was developed using samples from 115 patients [4].
This set of genes showed an accuracy of 63% (93% sensi-
tivity and 48% NPV) when tested on 171 additional
tumours. These two main studies (van't Veer et al. and
Wang et al.) have focused on detecting patients with good
prognosis where adjuvant chemotherapy is not required.
Interestingly, none of the genes used in these two studies
were found in our gene list, even though some genes
seems to be involved in the same pathways. Ein-Dor et al.
suggest that since many genes are similarly correlated to
breast cancer survival, several lists of genes from the same
data-set would be equally predictive [35]. These lists could
be rather trustworthy prognostic tools, but the specific
genes in the lists are not necessarily of importance for sur-
vival if considered individually.
When classifying van't Veer's tumours based on our gene-
list, the correlation-based classifier showed 74% accuracy
and 85% NPV. The corresponding percentage of correctly
classified tumours in van't Veer's study was 83% (88%
NPV). Overall, the average time of disease-free survival of
the five patients that were misclassified into the "good
prognosis group" was noticeably higher than for the
patients that were correctly classified into the "bad prog-
nosis group", although the difference fell short of being
statistically significant (41 months versus 28 months, p =
0,11). Moreover, 74% accuracy, especially with high NPV,
is a good result (figure 2b). Using the VFI method, 67% of
the tumours were classified correctly. The results would
probably have been even better if all genes in the gene list
could have been found in the material. The attempt to
classify Wang's data using our genes did not provide a
good correlation. This may be explained by the fact that
only 23 of our 51 genes could be found in their material.
Furthermore, not even Wang et al. themselves found par-
ticularly high accuracy when classifying their tumours
(63%). Still they could specify a sub-group of 56 patients
where 93% were free of metastasis within five years from
diagnosis, which we could not do with our gene set. In our
gene set, four genes were of special interest since they dif-
fered significantly in expression between the groups with
(p < 0.05) in van't Veer's data as well; GGH, PIR, TAF5L
and FAAH. Of these, only FAAH was significant in Wang's
data. This gene has earlier only been correlated to multi-
ple drug addiction [36]. In summary, our gene set had
high accuracy when classifying our own material and was
relatively competent in classifying the samples in van't
Veer's study, but did not show high accuracy on Wang's
tumours.
A correlation-based classifier showed 72% accuracy in
predicting 10-year survival (figure 3a) and the VFI classifi-
cation of our tumours using van't Veer's genes showed
67% accuracy. Hereby, the results both with the VFI clas-
sifier and the correlation-based classifier were moderate,
considering that the NPV was only 73%. Using Wang's
genes, the VFI classifier showed 70% accuracy which is
moderate, while the correlation-based classifier worked
poorly, showing only 61% accuracy and as many as twelve
deceased patients were classified in the "good prognosis
group" (figure 3b). In general, classifying a material is nat-
urally more accurate when using a set of genes selected for
that specific material. Moreover, the genes in our list seem
to be more accurate in predicting 10-year survival,
whereas van't Veer's and Wang's genes are likely to better
predict metastasis within five years.
Many of the 51 genes with significantly different expres-
sion between the two survival groups have previously
been implicated in cancer. The genes BCAT1, GGH and
SERPINB9  have been correlated to clinical outcome in
Kaplan-Meier survival curves over time for the patients  included in this study Figure 4
Kaplan-Meier survival curves over time for the 
patients included in this study. The correlation-based 
classifier classified the tumours into a "good prognosis 
group" and a "bad prognosis group". These Kaplan-Meier 
curves visualize the survival rate in the two groups the first 
ten years after diagnosis. The dashed line represents the 
good prognosis group and the black line represents the bad 
prognosis group.BMC Cancer 2008, 8:254 http://www.biomedcentral.com/1471-2407/8/254
Page 12 of 14
(page number not for citation purposes)
other types of cancer, such as colorectal cancer, neuroen-
docrine cancer, large cell lymphoma and melanoma [37-
40]. The genes SALL4 and TM4SF5 were expressed to a
higher extent in the tumours from deceased patients in
our material and have been reported to be up-regulated in
other cancers, and may thereby represent putative onco-
genes [41,42]. NEIL1, a gene involved in DNA repair [43],
showed lower expression levels in the tumours from
deceased patients in our material and has been reported as
down-regulated in gastric cancer [44]. The GIT2 gene was
higher expressed in the tumours from deceased patents
and may be implicated in the transformation of epithelial
cells to cancer cells as well as inducing cell motility and
invasion [45]. The genes CCNB1IP1, CUL7 and E2F2 are
involved in cell cycle control and cell growth [46-48] and
have expression levels in our study that promotes cell
growth in the tumours from deceased patients. In our pre-
vious CGH-study of the same tumours, seven chromo-
somal regions were altered significantly more in the
tumours from deceased patients than the tumours from
10-year survivors (4q, 5q, 6q, 12q, 17p, 18p and Xq) [16].
Five of the selected genes in the microarray study were
located in these regions (C4orf26,  CCDC99,  SPATA5,
TM4SF5 and TRPV2) and might be of special interest since
they revealed significance in both studies.
There are disadvantages using this type of selected mate-
rial for gene expression studies, the tumours in this study
come from a relatively homogenous population in Swe-
den which might make the results less applicable for
breast cancer tumours in general. Furthermore, the
number of tumours investigated in this study is low, fur-
ther studies using larger sets of tumours are needed to ver-
ify the significance of the 51 gene list. Also, the tumours
have been frozen for a long period of time which might
affect the quality of the RNA yielding less reliable results.
Conclusion
It can be concluded that the list of 51 genes we identified
(table 2) could predict clinical outcome in our material
with great certainty. They were competent in van't Veer's
as well but not in Wang's material, probably due to the
low number of genes found in the material. In classifying
our material, our gene set clearly worked best, but the
genes found by van't Veer et al. and Wang et al. had some
prognostic potential as well. The gene set found by Wang
et al. had the lowest impact on our material, particularly
considering the low NPV (59%) in the correlation based
classification. Overall, our gene set worked similarly well
in classifying van't Veer's material as their gene set on our
material, slightly better considering the NPV.
The list of 51 genes might contain specific genes interest-
ing for clinical outcome in breast cancer as well as being a
good prognostic gene set. Additional studies using larger
sets of tumours are needed to define the significance of
these genes during the genesis of lymph-node-negative
breast tumours.
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